Bellerophon Therapeutics Stock Current Valuation
| BLPHDelisted Stock | USD 0.71 0.01 1.43% |
Valuation analysis of Bellerophon Therapeutics helps investors to measure Bellerophon Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Bellerophon Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Bellerophon Therapeutics is based on 3 months time horizon. Increasing Bellerophon Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Bellerophon Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bellerophon Pink Sheet. However, Bellerophon Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.71 | Real 0.67 | Hype 0.71 |
The intrinsic value of Bellerophon Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Bellerophon Therapeutics' stock price.
Estimating the potential upside or downside of Bellerophon Therapeutics helps investors to forecast how Bellerophon pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bellerophon Therapeutics more accurately as focusing exclusively on Bellerophon Therapeutics' fundamentals will not take into account other important factors: Bellerophon Therapeutics Company Current Valuation Analysis
Bellerophon Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Bellerophon Therapeutics Current Valuation | (9.32 M) |
Most of Bellerophon Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bellerophon Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Bellerophon Therapeutics has a Current Valuation of (9.32 Million). This is 100.06% lower than that of the Health Care Equipment & Supplies sector and 100.2% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.06% higher than that of the company.
Bellerophon Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bellerophon Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bellerophon Therapeutics could also be used in its relative valuation, which is a method of valuing Bellerophon Therapeutics by comparing valuation metrics of similar companies.Bellerophon Therapeutics is currently under evaluation in current valuation category among its peers.
Bellerophon Fundamentals
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.6 | ||||
| Profit Margin | (2.20) % | ||||
| Operating Margin | (2.48) % | ||||
| Current Valuation | (9.32 M) | ||||
| Shares Outstanding | 12.23 M | ||||
| Shares Owned By Insiders | 3.97 % | ||||
| Shares Owned By Institutions | 45.08 % | ||||
| Number Of Shares Shorted | 90.45 K | ||||
| Price To Earning | 5.33 X | ||||
| Price To Book | 1.05 X | ||||
| EBITDA | (22.39 M) | ||||
| Net Income | (19.83 M) | ||||
| Cash And Equivalents | 16.33 M | ||||
| Cash Per Share | 1.71 X | ||||
| Total Debt | 203 K | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 3.12 X | ||||
| Book Value Per Share | 0.46 X | ||||
| Cash Flow From Operations | (17.77 M) | ||||
| Short Ratio | 1.26 X | ||||
| Earnings Per Share | (0.34) X | ||||
| Target Price | 2.0 | ||||
| Number Of Employees | 18 | ||||
| Beta | 0.55 | ||||
| Market Capitalization | 1.25 M | ||||
| Total Asset | 7.93 M | ||||
| Retained Earnings | (252.08 M) | ||||
| Working Capital | 2.16 M | ||||
| Current Asset | 29.45 M | ||||
| Current Liabilities | 8.07 M | ||||
| Z Score | -49.75 | ||||
| Net Asset | 7.93 M |
About Bellerophon Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bellerophon Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bellerophon Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bellerophon Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in Bellerophon Pink Sheet
If you are still planning to invest in Bellerophon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellerophon Therapeutics' history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |